Latest Breaking News On - Bristol myers squib - Page 8 : comparemela.com

REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, CM24, a first-in-class anti-CEACAM1 monoclonal antibody. Data were presented at the American Association for Cancer Research (AACR) Special Co

United statesGil efronHadas reuveniDrug administrationAmerican association for cancer researchPurple biotech ltdExchange commissionBristol myers squibbAmerican associationCancer researchSpecial conferencePancreatic cancerAdvanced pancreatic cancerExploratory biomarkersNeutrophil extracellular trapsPurple biotech